# A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting

> **NCT03021018** · PHASE2 · COMPLETED · sponsor: **UCB Biopharma S.P.R.L.** · enrollment: 46 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Brivaracetam
- **DRUG:** Lorazepam

## Key facts

- **NCT ID:** NCT03021018
- **Lead sponsor:** UCB Biopharma S.P.R.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-06
- **Primary completion:** 2018-04-27
- **Final completion:** 2018-04-27
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2020-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03021018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03021018, "A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03021018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*